How big is Longeveron, Inc.?

As of Jun 18, Longeveron, Inc. has a market capitalization of 18.31 million, with net sales of 2.22 million and a net profit of -16.92 million over the last four quarters. The company's shareholder's funds are 21.89 million, and total assets are 25.56 million.

Market Cap: As of Jun 18, Longeveron, Inc. has a market capitalization of 18.31 million, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Longeveron, Inc. reported net sales of 2.22 million and a net profit of -16.92 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 21.89 million, while total assets were reported at 25.56 million.

What does Longeveron, Inc. do?

Longeveron, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $0 million and a net loss of $5 million as of March 2025. It has a market cap of $18.31 million and key metrics indicating significant financial challenges.

Overview:<BR>Longeveron, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -5 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 18.31 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.80 <BR>Return on Equity: -98.64% <BR>Price to Book: 1.07 <BR><BR>Contact Details:<BR>Registrar Address: Not available.

Should I buy, sell or hold Longeveron, Inc.?

Is Longeveron, Inc. overvalued or undervalued?

As of August 14, 2024, Longeveron, Inc. is rated as risky due to its overvaluation and poor financial metrics, including a negative ROCE of -508.69%, a year-to-date return of -55.49% compared to the S&P 500's gain of 12.22%, indicating significant deterioration in its investment appeal.

As of 14 August 2024, the valuation grade for Longeveron, Inc. has moved from does not qualify to risky, indicating a significant deterioration in its investment appeal. The company appears to be overvalued given its negative financial metrics, including a Price to Book Value of 1.08, an EV to Sales ratio of 2.14, and a troubling ROCE of -508.69%. In comparison to its peers, Surrozen, Inc. has a P/E ratio of 7.84, while GeoVax Labs, Inc. shows a less negative EV to EBITDA of -0.5852, highlighting Longeveron's relative weakness in the market.<BR><BR>The stock has performed poorly against the S&P 500, with a year-to-date return of -55.49% compared to the index's gain of 12.22%. This stark contrast reinforces the notion that Longeveron is not only struggling financially but also failing to deliver value to its investors.

Is Longeveron, Inc. technically bullish or bearish?

As of September 2, 2025, Longeveron, Inc. shows a mildly bearish trend due to bearish signals from the weekly MACD and Bollinger Bands, despite some underlying strength indicated by monthly indicators, while significantly underperforming the S&P 500 with a year-to-date return of -55.49%.

As of 2 September 2025, the technical trend for Longeveron, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven primarily by the weekly MACD and Bollinger Bands both indicating bearish signals, while the daily moving averages also reflect a bearish trend. However, the monthly MACD and KST show mildly bullish tendencies, and the monthly RSI is bullish, suggesting some underlying strength. Despite this, the overall technical picture remains cautious. The company has significantly underperformed compared to the S&P 500, with a year-to-date return of -55.49% versus the benchmark's 12.22%, and a one-year return of -62.44% compared to 17.14% for the S&P 500.